


1103326-0250 (CON)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Depui, et al.
Serial No. : 10/620,000
Filed : 14 July 2003
For : ORAL PHARMACEUTICAL DOSAGE
FORMS COMPRISING A PROTON
PUMP INHIBITOR AND A NSAID
Examiner : Channavajjala, Lakshmi Sarda
Group Art Unit : 1615

**RECEIVED
CENTRAL FAX CENTER****FEB 20 2007**

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8	
I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on 20 February 2007 at the facsimile number 571-273-8300.	
John M. Genova	32,224
Attorney Name	PTO Reg. No.
	20 February 2007
Signature	Date of Signature

MAIL STOP OIPE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Examiner Channavajjala, Lakshmi Sarda
Pages: 4

Power of Attorney

Sir:

In connection with referenced patent application, Applicants submit herewith a copy of each of the original Statement under 37 C.F.R. §3.73(b) (PTO/SB/96) and Revocation of Power of Attorney with New Power of Attorney (PTO/SB/82) signed by an authorized representative of the patent assignee of record.

In view of the foregoing, power of attorney is given to all practitioners associated with Customer No. 007470 to transact any and all business in the U. S. Patent and Trademark Office in connection with the referenced patent application, including matters pertaining to Patent Interference No. 105,533 involving the referenced patent application.

FROM W&C 20FLOOR

(TUE) 2. 20' 07 13:44/ST. 13:44/NO. 4865014410 P 2

USSN 10/620,000, filed 14 July 2003
Attorney Docket No. 1103326-0250(CON)
Page 2 of 2

A copy of each of the forms submitted herewith is also being filed concurrently with the Board of Patent Appeals and Interferences in connection with Patent Interference 105,533.

Authorization is hereby given to charge any fee which may be due in connection with this communication to Deposit Account No. 23-1703.

Dated: 20 February 2007

Respectfully submitted,



John M. Genova
Reg. No. 32,224

Customer No. 007470
Attorney's Direct Dial 212-819-8832

RECEIVED
CENTRAL FAX CENTER

FEB 20 2007

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 12/31/2008. OMB 0551-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/620,000
Filing Date	July 14, 2003
First Named Inventor	Helen Depul
Title	Oral Pharmaceutical Dosage Forms...
Art Unit	
Examiner Name	
Attorney Docket Number	1109328-0250

I hereby revoke all previous powers of attorney given in the above-identified application.
I hereby appoint:

☒ Practitioners associated with the Customer Number:

007470

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number;

OR

☐ The address associated with Customer Number:

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City		State	Zip
Country			
Telephone		Email	

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature			Date	16 February 2007
Name	Bo Hasslev		Telephone	+46 8 553 286131
Title and Company	Director IP Finance and Information			

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

FEB 20 2007

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: AstraZeneca AB

Application No./Patent No.: Appl. No. 10/820,000 Filed/Issue Date: July 14, 2003

Entitled: Oral Pharmaceutical Dosage Forms Comprising a Proton Pump Inhibitor and a NSAID

AstraZeneca AB, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or

2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____ or for which a copy thereof is attached.

OR

B ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Inventors To: Astra Aktiebolag
The document was recorded in the United States Patent and Trademark Office at Reel 9029, Frame U518, or for which a copy thereof is attached.

2. From: Astra Aktiebolag To: AstraZeneca AB
The document was recorded in the United States Patent and Trademark Office at Reel 012492, Frame 0470, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

[Signature] Signature
Bo Hasslev
Printed or Typed Name
Director IP Finance and Information

16 February 2007
Date
+46 8 553 286 31
Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8199 and select option 2.